A KOL interview addressing the current treatment landscape in ovarian cancer and the need to develop effective therapies in the relapsed/resistant settings, as well as in low-grade serous ovarian cancer. Clinical trials for immunotherapies in ovarian cancer are discussed, as well as pipeline drugs in development against novel targets. 

This interview was conducted on 11 April 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.